CD36 and peripheral arterial disease: In conclusion, our data indicate an inhibitory effect of rivaroxaban on the thrombin propagation phase of platelet CD36-sensitive thrombin formation in patients with PAD treated with ASA plus rivaroxaban compared to ASA monotherapy, which is more pronounced than during ASA plus clopidogrel therapy.